Articles tagged with Chimeric Antigen Receptor Therapy
Researchers at Case Western Reserve University have developed a new device called CAPGLO that uses magnets to isolate disease-fighting T cells, making CAR T cell therapy potentially less expensive and more accessible. The technology aims to reduce the cost of immunotherapy from thousands to just hundreds of dollars.
Four researchers — Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain — are awarded the Merkin Prize for developing CAR T-cell therapy, a groundbreaking form of personalized cancer immunotherapy. The technology has led to durable remissions in tens of thousands of patients with previously incurable blood cancers.
Researchers found that aging impairs CAR-T cell function and antitumor activity due to lower NAD levels. Rejuvenating aged cells with NAD-boosting compounds improves their effectiveness.
A new strategy for treating B-cell lymphoma has shown promising results with a next-generation CAR T cell therapy that incorporates IL18. The treatment achieved high remission rates of 81% and complete remission in 52%, with some patients experiencing durable responses lasting two years or more.
Researchers at Osaka University identify a specific molecule, HLA-DRB1, that can be targeted by CAR-based therapy for AML. Engineered CAR T cells showed strong and specific anti-AML effects in vitro and in vivo with mice, without overt toxicity.
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
A new liposarcoma treatment using CAR T cells has shown promising results in clinical trials, with a response rate of 20-40% in patients with advanced or metastatic disease. Additionally, researchers have developed more efficient drug-delivery nanoparticles that can improve cancer treatment outcomes.
Scientists at Goethe University Frankfurt have discovered a new way to tailor natural killer cells to target leukemia cells, improving their efficacy. The researchers used CRISPR/Cas9 gene editing to disable an immune checkpoint, allowing the modified cells to attack cancer cells more effectively.
Researchers used lab-grown organoids from glioblastoma tumors to model patient response to CAR T cell therapy. The organoids accurately reflected the treatment's effect on actual tumors, providing a promising tool for personalized medicine.
A new study found that CAR-T cell therapy success is predicted by three key features: the CD4/CD8 ratio in infusion products, the presence of T-cell exhaustion signals before infusion, and the expansion of T-cells during therapy. These factors can help improve treatment outcomes.
Researchers have discovered a novel immunotherapy approach using natural killer T cells to combat solid tumors. By targeting tumor-associated macrophages and promoting systemic immune responses, CAR-natural killer T cells demonstrate superior antitumor activity compared to traditional CAR-T therapy.
A recent study suggests that the two-week toxicity monitoring period for CAR-T therapy in diffuse large B-cell non-Hodgkin lymphoma patients is too restrictive, with most toxicities occurring within the first two weeks. Shortening this period and reducing driving restrictions could increase treatment accessibility for patients.
Researchers developed a method using lipid nanoparticles to activate T cells and deliver genetic instructions in one step, simplifying the CAR T cell manufacturing process. This new approach reduces production time from 48 hours to 24 hours and increases accessibility to patients worldwide.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
A new study suggests that magnetic resonance imaging (MRI) and lumbar puncture may not be necessary for diagnosing and managing immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy recipients. EEG findings often led to adjustments in medications, indicating its continued importance as a diagnostic tool.
Researchers at Memorial Sloan Kettering Cancer Center have engineered CAR T cells to target senescent cells, which can lead to chronic inflammation with aging. The treatment improved metabolic function in older mice and prevented decline later in life, suggesting potential benefits for diseases associated with aging.
A study published in Blood Advances found liso-cel to be a cost-effective treatment for r/r DLBCL, with a lower societal ICER of $68,212 per QALY. The treatment offered improved quality-adjusted life years and reduced lost productivity costs.
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
Researchers developed a technology to rapidly screen genetic edits in immune cells, identifying a new combination that improves their effectiveness against cancers. By combining multiple genes into long DNA stretches and testing thousands of combinations, scientists discovered that different CARs can be optimized by different factors.
A new EIC project, CAR T-REX, will develop novel, scalable CAR T cell therapies for the treatment of solid tumors. The consortium aims to overcome current limitations, including high manufacturing costs and limited efficacy, through a novel paradigm for generating improved CAR T cells.
A new study finds no significant difference in overall survival or complete remission rates between children and young adults with different levels of poverty exposure, regardless of their neighborhood opportunity. CAR T-cell therapy is equally effective for those from disadvantaged households as it is for those from more socioeconomic...
Researchers produce large quantities of powerful cancer-fighting iNKT cells using stem cell engineering and organoid technology, offering a potential solution for mass-producing an off-the-shelf immune cell therapy. The therapy, which uses hematopoietic stem cell-engineered iNKT cells, has been shown to be effective in killing multiple...